Abnormal expression of growth differentiation factor 9 and bone morphogenetic protein 15 in stimulated oocytes during maturation from women with polycystic ovary syndrome

• Published in: Fertility and sterility Vol. 96; no. 2; pp. 464 - 468
• Main Authors: Wei, Li-Na, Ph.D, Liang, Xiao-Yan, M.D, Fang, Cong, Ph.D, Zhang, Min-Fang, B.M
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.08.2011; Elsevier
• Subjects: Adult; animal ovaries; Biological and medical sciences; bone morphogenetic protein 15; Bone Morphogenetic Protein 15 - genetics; bone morphogenetic proteins; Case-Control Studies; China; Female; Female genital diseases; Fertility Agents, Female - therapeutic use; Gene Expression Regulation; germinal vesicle; Growth differentiation factor 9; Growth Differentiation Factor 9 - genetics; Gynecology. Andrology. Obstetrics; Hospitals, University; Humans; Internal Medicine; Medical sciences; messenger RNA; metaphase; Non tumoral diseases; Obstetrics and Gynecology; oocyte maturation; oocyte quality; Oocytes - diagnostic imaging; Oocytes - drug effects; Oocytes - metabolism; Ovulation Induction; patients; polycystic ovary syndrome; Polycystic Ovary Syndrome - diagnostic imaging; Polycystic Ovary Syndrome - drug therapy; Polycystic Ovary Syndrome - genetics; Polycystic Ovary Syndrome - physiopathology; RNA, Messenger - metabolism; Time Factors; Ultrasonography; women; oocyte maturation; oocyte quality; Growth differentiation factor 9; bone morphogenetic protein 15; polycystic ovary syndrome; Human; Gynecology; Female sterility; Polycystic ovary; Obstetrics; Protein; Female genital diseases; Ovarian diseases; Quality; Cyst; Female; Benign neoplasm; Bone; Differentiation; Woman; Oocyte; Growth factor; Oocyte maturation
• ISSN: 0015-0282; 1556-5653
• DOI: 10.1016/j.fertnstert.2011.05.036

Objective To investigate the expression pattern of two oocyte-secreted factors—growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BM15)—during oocyte maturation in women with polycystic ovary syndrome (PCOS) and in controls and to evaluate the expression differences in oocytes between the two groups. Design Case-control study. Setting University-affiliated hospital. Patient(s) Twenty-five oocytes were obtained from 12 patients with PCOS and 82 oocytes from 56 controls. Intervention(s) None. Main Outcome Measure(s) The abundance of GDF9 and BMP15 mRNA in oocytes of the germinal vesicle (GV), metaphase I (MI), and MII stage. Result(s) The expression of GDF9 and BMP15 mRNA displayed dynamic changes during oocyte maturation in controls after ovarian stimulation, with a decline at the MI stage and an increase to the peak at the MII stage. However, their expression in oocytes from patients with PCOS demonstrated a reduced state without any dynamic change. Conclusion(s) The results suggest that the expression of GDF9 and BMP15 in oocytes from patients with PCOS cannot reach the normal level even after ovarian stimulation and that the expression pattern is abnormal during oocyte maturation, which may be associated with impaired oocyte quality and developmental competence in PCOS.